drugset / Trial / NCT07062354
Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
Phase 2
Enrolling by invitation
50 enrolled
SWOG Cancer Research Network
Janssen Medical Affairs · collabSWOG Clinical Trials Partnerships, LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is for people who have head and neck cancer that has come back or spread to other places in the body.
Timeline
- Start
- 2026-03-25
- Primary completion
- 2028-10
- Completion
- 2029-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amivantamab | Monoclonal antibody | — | Subcutaneous |